Atossa Therapeutics’ (ATOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report report published on Thursday,Benzinga reports. They currently have a $7.00 price objective on the stock.

Several other analysts have also commented on ATOS. Ascendiant Capital Markets boosted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th.

Atossa Therapeutics Trading Down 2.6 %

NASDAQ ATOS opened at $1.12 on Thursday. Atossa Therapeutics has a 1-year low of $0.70 and a 1-year high of $2.31. The company has a market capitalization of $140.90 million, a price-to-earnings ratio of -5.09 and a beta of 1.21. The stock’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its position in Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Atossa Therapeutics in the second quarter valued at about $161,000. Barclays PLC lifted its position in Atossa Therapeutics by 280.9% during the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after buying an additional 123,683 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.